![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients’ quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α2 adrenergic receptor agonist activity. The goal of this article is to discuss current treatment options for rosacea and the properties of brimonidine tartate as well as the evidence surrounding its efficacy and safety profile.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Key issues
Facial erythema is an integral symptom of rosacea, a chronic skin condition.
Facial erythema is often difficult to treat and can often be disfiguring and debilitating, thus negatively impacting patient quality of life.
Brimonidine tartrate, which has previously been used to effectively treat ocular hypertension and open-angle glaucoma, has recently been approved by the US FDA in topical form to treat facial erythema of rosacea in adults.
Brimonidine tartrate gel has been shown to be both safe and efficacious with a low side effect profile.
Since its FDA approval, brimonidine tartrate gel has continued to be well tolerated with no related serious or systemic adverse events reported.